Literature DB >> 3280625

Do corticosteroids prevent postherpetic neuralgia? A review of the evidence.

B T Post1, J T Philbrick.   

Abstract

A short course of corticosteroids is frequently used in herpes zoster to prevent postherpetic neuralgia. To clarify the evidence behind this routine practice, we reviewed the three randomized controlled trials on this subject. Although in all three similar dosages of corticosteroids (40 mg to 60 mg prednisone daily for 2 to 4 weeks) were used, deficiencies in reported clinical characteristics of study subjects, the potential for bias in the ascertainment of pain duration, and the inability to exclude type II error make it impossible to determine whether or not this practice is effective. More research on this subject is needed, with greater attention to good study methodology.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3280625     DOI: 10.1016/s0190-9622(88)70082-1

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  8 in total

1.  Approches actuelles au traitement du zona: Aspects controversés du traitement du zona.

Authors:  R Bissonnette; G Leclerc
Journal:  Can Fam Physician       Date:  1992-04       Impact factor: 3.275

Review 2.  Treatment of shingles and post-herpetic neuralgia.

Authors:  J V Jolleys
Journal:  BMJ       Date:  1989-06-10

Review 3.  Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials.

Authors:  T Lancaster; C Silagy; S Gray
Journal:  Br J Gen Pract       Date:  1995-01       Impact factor: 5.386

Review 4.  Pharmacologic management of herpes zoster and postherpetic neuralgia.

Authors:  F S Mamdani
Journal:  Can Fam Physician       Date:  1994-02       Impact factor: 3.275

Review 5.  Varicella zoster virus. Recent advances in management.

Authors:  P Rajan; J K Rivers
Journal:  Can Fam Physician       Date:  2001-11       Impact factor: 3.275

Review 6.  Antiviral therapy of acute herpes zoster in older patients.

Authors:  K Herne; R Cirelli; P Lee; S K Tyring
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

7.  [Pain therapy in herpes zoster and post-zoster neuralgia.].

Authors:  T Zenz; M Zenz; M Tryba
Journal:  Schmerz       Date:  1994-03       Impact factor: 1.107

Review 8.  The cancer patient with chronic pain due to herpes zoster.

Authors:  S Modi; J Pereira; J R Mackey
Journal:  Curr Rev Pain       Date:  2000
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.